IDEXX Laboratories (IDXX)
Market Price (12/4/2025): $725.02 | Market Cap: $58.1 BilSector: Health Care | Industry: Health Care Equipment
IDEXX Laboratories (IDXX)
Market Price (12/4/2025): $725.02Market Cap: $58.1 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, Digital Health & Telemedicine, and Sustainable Resource Management. Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, Digital Health & Telemedicine, and Sustainable Resource Management. Show more. |
Valuation, Metrics & Events
IDXX Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
The search results provide substantial information for IDEXX Laboratories (IDXX) during the specified period of August 31, 2025, to December 4, 2025. This includes Q2 and Q3 2025 earnings reports, analyst ratings, and strategic developments. I can now extract the key points. Here's a breakdown of relevant information from the search results: **Q2 2025 Earnings (Reported August 4, 2025):** * IDEXX Laboratories reported strong Q2 2025 results, exceeding analyst expectations for EPS ($3.63 vs. forecasted $3.29) and revenue ($1.11 billion vs. $1.06 billion). * The company raised its full-year 2025 guidance for both EPS ($12.40-$12.76) and revenue ($4.205 billion-$4.280 billion). * Stock surged significantly (e.g., 26.59% on August 4, 2025, according to one source, and over 20% by another) following the Q2 earnings announcement. * Strong performance was driven by innovation in diagnostics, global commercial execution, and record quarterly instrument placements (including nearly 2,400 IDEXX inVue Dx placements). * Operating profit increased and gross margins expanded. **Q3 2025 Earnings (Reported November 3, 2025):** * IDEXX reported impressive third-quarter results, exceeding EPS expectations ($3.40 vs. forecasted $3.14 or $3.13) and revenue ($1.1 billion or $1.105 billion, surpassing anticipated $1.07 billion or $1.07 billion). * This resulted in a 2.8% revenue surprise. * The company further increased its 2025 revenue guidance to $4.270 billion - $4.300 billion and raised its 2025 EPS outlook to $12.81 - $13.01. * Strong organic revenue growth was supported by IDEXX's innovation, including over 1,700 IDEXX inVue Dx placements. * Operating margin expanded by 100-120 basis points. * The stock closed up by 14.8% on November 3 after Q3 results. **Analyst Ratings and Outlook:** * Several analysts maintained or raised price targets and ratings. Stifel Nicolaus maintained a "Buy" rating with a price target of $775.00 (November 21, 2025). * Morgan Stanley raised its price objective to $805.00 with an "overweight" rating (November 4). * UBS Group increased its price target to $750.00 (November 4). * Zacks upgraded IDEXX to a Zacks Rank #2 (Buy) on November 28, 2025, due to an upward trend in earnings estimates. * The consensus rating is "Moderate Buy" with an average price target of $730.50-$785.27. * Forecasts predict IDXX shares will rise by 11.43% and reach $838.93 per share by December 30, 2025, with an average annualized price of $786.21, representing a potential return on investment of 13.24% compared to current rates. **Insider Transactions:** * EVP Nimrata Hunt sold 9,425 shares for a total value of $6,628,979.50 on November 7, 2025. This exceeds the $5 million threshold. Considering the period from 8/31/2025 to today (12/4/2025), the Q3 earnings report and subsequent analyst actions are highly relevant. The Q2 earnings, while reported just before the start of the period (August 4, 2025), had a significant positive impact that would have carried into the beginning of the specified timeframe and influenced subsequent analyst ratings and investor confidence. The stock was already "trading up by 27.75%" on August 4, 2025, due to positive earnings, which sets a positive tone for the period. Let's synthesize the top 5 key points explaining why the stock moved by 12.2% (or showed significant positive movement). 1. **Strong Q2 2025 Financial Performance and Upbeat Guidance:** Although reported slightly before the period, the robust Q2 2025 earnings, which beat EPS and revenue estimates, and the subsequent increase in full-year 2025 guidance, created significant positive momentum for the stock leading into and during the beginning of the specified period. 2. **Exceptional Q3 2025 Earnings Beat and Raised Outlook:** The company's third-quarter 2025 results, released on November 3, 2025, again surpassed analyst expectations for both earnings per share and revenue, and management further raised its full-year 2025 revenue and EPS guidance. This "impressive" performance led to increased investor confidence and positive price momentum. 3. **Positive Analyst Sentiment and Increased Price Targets:** Multiple research firms maintained or upgraded their ratings and significantly increased price targets for IDEXX, reflecting strong confidence in the company's future growth potential and strategic direction. 4. **Innovation-Driven Growth and Product Placements:** IDEXX demonstrated strong execution of its innovation-driven growth strategy, highlighted by robust global commercial performance and record quarterly instrument placements, including new products like IDEXX inVue Dx. This drove organic revenue growth and strengthened the company's market position. 5. **Significant Institutional Investor Confidence (despite insider selling):** Despite an insider selling shares exceeding $5 million (EVP Nimrata Hunt sold over $6.6 million in November), institutional investors largely remained bullish on IDEXX, with several increasing their positions, indicating continued confidence in the company's future performance.
Show moreStock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IDXX Return | 91% | 32% | -38% | 36% | -26% | 77% | 181% |
| Peers Return | 1% | 12% | -20% | 12% | 11% | 41% | 60% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| IDXX Win Rate | 75% | 58% | 42% | 50% | 42% | 60% | |
| Peers Win Rate | 56% | 60% | 42% | 54% | 50% | 50% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| IDXX Max Drawdown | -30% | -7% | -51% | -4% | -27% | -13% | |
| Peers Max Drawdown | -33% | -9% | -37% | -17% | -17% | -27% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: MRK, ZTS, ELAN, PAHC, DAVI. See IDXX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | IDXX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -54.0% | -25.4% |
| % Gain to Breakeven | 117.4% | 34.1% |
| Time to Breakeven | 1116 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -37.1% | -33.9% |
| % Gain to Breakeven | 59.1% | 51.3% |
| Time to Breakeven | 45 days | 148 days |
| 2018 Correction | ||
| % Loss | -30.8% | -19.8% |
| % Gain to Breakeven | 44.4% | 24.7% |
| Time to Breakeven | 151 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -57.3% | -56.8% |
| % Gain to Breakeven | 134.1% | 131.3% |
| Time to Breakeven | 519 days | 1480 days |
Compare to MRK, ZTS, ELAN, PAHC, DAVI
In The Past
IDEXX Laboratories's stock fell -54.0% during the 2022 Inflation Shock from a high on 8/5/2021. A -54.0% loss requires a 117.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
Trade Ideas
Select past ideas related to IDXX. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| 01312025 | IDXX | IDEXX Laboratories | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 26.9% | 73.6% | -14.5% |
| 07312024 | IDXX | IDEXX Laboratories | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -12.0% | 12.2% | -24.2% |
| 06302022 | IDXX | IDEXX Laboratories | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 17.0% | 43.2% | -7.4% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| 01312025 | IDXX | IDEXX Laboratories | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 26.9% | 73.6% | -14.5% |
| 07312024 | IDXX | IDEXX Laboratories | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -12.0% | 12.2% | -24.2% |
| 06302022 | IDXX | IDEXX Laboratories | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 17.0% | 43.2% | -7.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for IDEXX Laboratories
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | - |
| Mkt Cap | - |
| Rev LTM | - |
| Op Inc LTM | - |
| FCF LTM | - |
| FCF 3Y Avg | - |
| CFO LTM | - |
| CFO 3Y Avg | - |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | - |
| Rev Chg 3Y Avg | - |
| Rev Chg Q | - |
| QoQ Delta Rev Chg LTM | - |
| Op Mgn LTM | - |
| Op Mgn 3Y Avg | - |
| QoQ Delta Op Mgn LTM | - |
| CFO/Rev LTM | - |
| CFO/Rev 3Y Avg | - |
| FCF/Rev LTM | - |
| FCF/Rev 3Y Avg | - |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | - |
| P/S | - |
| P/EBIT | - |
| P/E | - |
| P/CFO | - |
| Total Yield | - |
| Dividend Yield | - |
| FCF Yield 3Y Avg | - |
| D/E | - |
| Net D/E | - |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | - |
| 3M Rtn | - |
| 6M Rtn | - |
| 12M Rtn | - |
| 3Y Rtn | - |
| 1M Excs Rtn | - |
| 3M Excs Rtn | - |
| 6M Excs Rtn | - |
| 12M Excs Rtn | - |
| 3Y Excs Rtn | - |
Comparison Analyses
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11032025 | 10-Q 9/30/2025 |
| 6302025 | 8042025 | 10-Q 6/30/2025 |
| 3312025 | 5012025 | 10-Q 3/31/2025 |
| 12312024 | 2212025 | 10-K 12/31/2024 |
| 9302024 | 10312024 | 10-Q 9/30/2024 |
| 6302024 | 8062024 | 10-Q 6/30/2024 |
| 3312024 | 5012024 | 10-Q 3/31/2024 |
| 12312023 | 2222024 | 10-K 12/31/2023 |
| 9302023 | 11012023 | 10-Q 9/30/2023 |
| 6302023 | 8012023 | 10-Q 6/30/2023 |
| 3312023 | 5022023 | 10-Q 3/31/2023 |
| 12312022 | 2162023 | 10-K 12/31/2022 |
| 9302022 | 11012022 | 10-Q 9/30/2022 |
| 6302022 | 8022022 | 10-Q 6/30/2022 |
| 3312022 | 5042022 | 10-Q 3/31/2022 |
| 12312021 | 2162022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |